Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 PK and safety comparison of OPB-111077 current vs modified formulations in healthy Japanese males
jRCT2071230033Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of OPB-111077 in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoints: Safety and tolerability of OPB-111077 current and modified formulations and Pharmacokinetics of OPB-111077 and its metabolites. Started Aug 2023; status: completed.
02
Drugs
OPB-111077
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on jRCT2071230033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230033.